The Teva Biosimilars Trend Report: Perspectives from Managed Care, Providers & Employers

On behalf of Teva Pharmaceuticals, we are pleased to present The Teva Biosimilars Trend Report, Vol. I. This report examines current developments in the rapidly evolving biosimilars market from the perspective of managed care professionals, providers, and employers. The report provides actionable insights into the adoption and utilization of biosimilars from each stakeholder perspective.¹

The report features national surveys conducted in the spring of 2023 with 55 decision-makers at managed care plans, 65 prescribers of biologic therapies (from rheumatology, gastroenterology, and dermatology specialties), and 37 executives representing employers and business coalitions. It also includes:

• Three chapters covering the perspectives of managed care payers, health care providers, and employers.
• Responses analyzed by independent experts representing each topic area. Nine experts also provide commentary on the findings and share their own experiences in the biosimilars space.
• Discussions of real-world challenges and opportunities to boost biosimilar adoption and realize cost savings.

Reference

1. Sonnenreich P, Leo S, Sciorra G, eds. The Teva Biosimilars Trend Report, Vol. 1.